With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From CSL Behring

Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.

US FDA approval for Shire PLC’s Takhzyro as a subcutaneous prophylactic for attacks of hereditary angioedema should position the company to begin winning back market share lost to CSL Behring’s prophylactic agent Haegarda. Analysts predict rapidly ramping sales for Takhzyro, reaching blockbuster totals in just a few years.

Unlike Haegarda, which inhibits HAE patients’ C1 esterase levels, Takhzyro (lanadelumab-flyo) is a kallikrein-inhibiting monoclonal antibody. It is the first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By 

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

More from Scrip

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Executives On The Move: Three New CEOs And CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.